Vistagen reports safety and efficacy data from fasedienol OLE study

September 22, 2026 8:30 AM

Vistagen (Nasdaq: VTGN) released preliminary data from the open-label extension (OLE) portion of its PALISADE-4 Phase 3 study of fasedienol ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found